Abstract
Background: The survival of patients with ovarian cancer has improved because of surgery and chemotherapy. This study aimed to estimate the changes in survival rates among Korean women with ovarian cancer prior to the introduction of targeted therapy for ovarian cancer. Methods: Data were obtained from the Korea Central Cancer Registry regarding patients who were diagnosed with epithelial ovarian cancer between 1995 and 2014. The relative survival rates were calculated for 5-year periods using the Ederer II method. Cox proportional hazard models were created to assess the associations of demographic and clinicopathological factors with ovarian cancer survival. Results: During the study period, 22,880 women were diagnosed with epithelial ovarian cancer. The 5-year relative survival rate improved from 57.2% during 1995-1999 to 63.8% during 2010-2014 (P<0.001). Survival outcomes improved between 1995 and 1999 and 2010-2014 for the serous and endometrioid carcinoma subtypes (P<0.001). However, no improvements were observed for the mucinous and clear cell carcinoma subtypes (P=0.189 and P=0.293, respectively). Multivariate analysis revealed that younger age, early stage, recent diagnosis, primary surgical treatment, and non-serous histological subtype were favorable prognostic factors. Conclusion: Survival outcomes have improved for serous and endometrioid epithelial ovarian cancer in the last 20 years. However, no improvement was observed for patients with mucinous and clear cell carcinoma subtypes.
| Original language | English |
|---|---|
| Article number | 601 |
| Journal | BMC cancer |
| Volume | 18 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2018 May 29 |
Bibliographical note
Funding Information:This study was supported in part by a National Cancer Center Grant (Grant No. NCC-1610200) and a new faculty research seed money grant of Yonsei University College of Medicine for 2017 (Grant No. 2017-32-0033). The funding bodies played no role in the design and conduct of the study; collection, analysis, and interpretation of data; writing of the manuscript, and the decision to submit the manuscript for publication
Funding Information:
This study was supported in part by a National Cancer Center Grant (Grant No. NCC-1610200) and a new faculty research seed money grant of Yonsei University College of Medicine for 2017 (Grant No. 2017–32-0033). The funding bodies played no role in the design and conduct of the study; collection, analysis, and interpretation of data; writing of the manuscript, and the decision to submit the manuscript for publication.
Publisher Copyright:
© 2018 The Author(s).
All Science Journal Classification (ASJC) codes
- Oncology
- Genetics
- Cancer Research
